NASDAQ:RDNTRadNet Stock Price, Forecast & News

RadNet's stock was trading at $17.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RDNT shares have decreased by 1.7% and is now trading at $16.93. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for RadNet in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for RadNet.

RadNet is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for RadNet.

RadNet Inc. (NASDAQ:RDNT) released its quarterly earnings data on Monday, May, 11th. The medical research company reported ($0.33) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.16. The medical research company earned $281.60 million during the quarter, compared to the consensus estimate of $242.09 million. RadNet had a net margin of 0.18% and a return on equity of 1.56%. The business's quarterly revenue was up 3.7% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.08) EPS. View RadNet's earnings history.

RadNet updated its FY 2020 Pre-Market earnings guidance on Thursday, March, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.175-1.225 billion, compared to the consensus revenue estimate of $1.2 billion.

1 analysts have issued twelve-month price targets for RadNet's shares. Their forecasts range from $23.00 to $23.00. On average, they anticipate RadNet's stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 35.9% from the stock's current price. View analysts' price targets for RadNet.

News stories about RDNT stock have trended very positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. RadNet earned a media sentiment score of 3.5 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutRadNet.

RadNet saw a increase in short interest in April. As of April 30th, there was short interest totaling 1,410,000 shares, an increase of 6.0% from the April 15th total of 1,330,000 shares. Based on an average daily volume of 482,500 shares, the days-to-cover ratio is presently 2.9 days. Approximately 3.3% of the shares of the stock are sold short. View RadNet's Current Options Chain.

Some companies that are related to RadNet include Natera (NTRA), InVitae (NVTA), CareDx (CDNA), Veracyte (VCYT), Castle Biosciences (CSTL), Fulgent Genetics (FLGT), Personalis (PSNL), Centogene (CNTG), DermTech (DMTK), Enzo Biochem (ENZ), Celcuity (CELC), Anpac Bio-Medical Science (ANPC), Biocept (BIOC), Miragen Therapeutics (MGEN) and Psychemedics (PMD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other RadNet investors own include Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Rigel Pharmaceuticals (RIGL), AT&T (T), UnitedHealth Group (UNH), Boeing (BA), Alibaba Group (BABA) and NovaBay Pharmaceuticals (NBY).

RadNet trades on the NASDAQ under the ticker symbol "RDNT."

RadNet's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.45%), Beck Mack & Oliver LLC (3.74%), State Street Corp (2.58%), Global Alpha Capital Management Ltd. (2.17%), Silvercrest Asset Management Group LLC (2.00%) and Dalton Greiner Hartman Maher & Co. (1.99%). Company insiders that own RadNet stock include B Kaplan Survivor's Tru Karen, David L Swartz, Jeffrey L Linden, John V Crues, Mark Stolper, Michael L Md Sherman, Michael N Murdock and Norman R Hames. View institutional ownership trends for RadNet.

RDNT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Invesco Ltd., Morgan Stanley, Deutsche Bank AG, Russell Investments Group Ltd., Cheyne Capital Management UK LLP, Victory Capital Management Inc., and Victory Capital Management Inc.. Company insiders that have sold RadNet company stock in the last year include John V Crues, Mark Stolper, Michael L Md Sherman, Michael N Murdock, and Norman R Hames. View insider buying and selling activity for RadNet.

RDNT stock was purchased by a variety of institutional investors in the last quarter, including Beck Mack & Oliver LLC, Silvercrest Asset Management Group LLC, Dalton Greiner Hartman Maher & Co., Assenagon Asset Management S.A., Voce Capital Management LLC, Hennessy Advisors Inc., State Street Corp, and JPMorgan Chase & Co.. View insider buying and selling activity for RadNet.

Shares of RDNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RDNT stock can currently be purchased for approximately $16.93.

RadNet has a market capitalization of $858.27 million and generates $1.15 billion in revenue each year. The medical research company earns $14.76 million in net income (profit) each year or $0.29 on an earnings per share basis. RadNet employs 8,498 workers across the globe.

The official website for RadNet is www.radnet.com.

RadNet's mailing address is 1510 COTNER AVE, LOS ANGELES CA, 90025. The medical research company can be reached via phone at 310-478-7808 or via email at [email protected]